Astellas Signs Strategic Oncology Partnership With Ambit After Medivation Success
This article was originally published in PharmAsia News
Executive Summary
Just days after Takeda signed a strategic alliance with Seattle Genetics for oncology antibody drug development, Astellas announced Dec. 18 a worldwide agreement with San Diego-based Ambit Bioscience to jointly develop and commercialize FMS-like tyrosine kinase-3 inhibitors for multiple oncology and non-oncology indications
You may also be interested in...
Looking for Oncology Payoff, Astellas Makes Hostile Bid for Tarceva Maker OSI
Astellas Pharma is going hostile again. The Japanese drug maker launched a $3.5 billion unsolicited bid for OSI Pharmaceuticals on March 1 to gain a foothold in the oncology market
Looking for Oncology Payoff, Astellas Makes Hostile Bid for Tarceva Maker OSI
Astellas Pharma is going hostile again. The Japanese drug maker launched a $3.5 billion unsolicited bid for OSI Pharmaceuticals on March 1 to gain a foothold in the oncology market
Astellas Increases R&D To Bridge Prograf, Flomax Patent Losses
Japan's second-largest drug maker Astellas estimates net profit is down by 27 percent to ¥125 billion ($1.375 billion) for fiscal year 2009, due largely to decreasing sales from patent losses in major products Prograf (tacrolimus) and Flomax (tamsulosin) and increasing research and development expenses to cultivate new products